| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | 0.17 | 5e-06 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0006 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | Pazopanib | GDSC1000 | pan-cancer | AAC | 0.1 | 0.002 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | 0.14 | 0.003 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.098 | 0.004 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | 0.22 | 0.004 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.097 | 0.007 |
| mRNA | NSC23766 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.009 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.08 | 0.009 |